Boston Scientific has acquired the Baylis Medical Company

Boston Scientific has acquired Baylis Medical Company for one-point-seven-five billion to expand the Boston Scientific structural and electrophysiology heart product portfolios. In 2022, Baylis Medical is predicted to earn net sales of $200 million after achieving a double-digit year-over-year sales increase in each of the previous five years.

Chairman and Chief Executive Officer, Boston Scientific, Mike Mahoney, stated: “The talented and innovative Baylis Medical Company team, combined with these transseptal platforms, will enhance our efforts to improve procedural efficiencies with physician tools designed to make left atrial access safer and more predictable, with a focus on patient outcomes. A leader in many of the fastest-growing markets in our industry, we believe that Baylis Medical Company will add meaningful revenue, operating income and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios.”